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Filoviruses, including Ebola, have the potential to be transmitted via virus-laden droplets deposited onto mucus membranes. 
Protecting against such emerging pathogens will require understanding how they may transmit at mucosal surfaces and developing 
strategies to reinforce the airway mucus barrier. Here, we prepared Ebola pseudovirus (with Zaire strain glycoproteins) and used 
high-resolution multiple-particle tracking to track the motions of hundreds of individual pseudoviruses in fresh and undiluted 
human airway mucus isolated from extubated endotracheal tubes. We found that Ebola pseudovirus readily penetrates human air-
way mucus. Addition of ZMapp, a cocktail of Ebola-binding immunoglobulin G antibodies, effectively reduced mobility of Ebola 
pseudovirus in the same mucus secretions. Topical delivery of ZMapp to the mouse airways also facilitated rapid elimination of 
Ebola pseudovirus. Our work demonstrates that antibodies can immobilize virions in airway mucus and reduce access to the air-
way epithelium, highlighting topical delivery of pathogen-specific antibodies to the lungs as a potential prophylactic or therapeutic 
approach against emerging viruses or biowarfare agents.
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Ebola virus readily infects many cell types, including immune 
cells, fibroblasts, endothelial cells, and epithelial cells [1, 2]. 
Given this broad tissue tropism, effective treatments of systemic 
Ebola infection generally require high doses of therapeutic 
molecules administered systemically. For instance, ZMapp, 
a cocktail of 3 chimeric monoclonal antibodies (Abs), was 
evaluated at 50 mg/kg in a randomized, controlled clinical trial 
in Guinea, Sierra Leone, and Liberia during the 2014–2016 
Ebola outbreak [3].
Rather than treating Ebola infections systemically, a poten-
tial alternative strategy is to block or treat infections at the por-
tals of entry before virions proliferate and spread throughout 
the body. In addition to transmission by direct contact with 
the blood, bodily fluids, or skin of Ebola-positive individuals 
[4–6], it is possible Ebola may be transmitted via virus-laden 
droplets generated from a heavily infected individual by cough-
ing, sneezing, vomiting, or medical procedures that are then 
directly propelled onto the mucus membranes of a nearby per-
son [5, 7]. We use the term droplet-based aerosol transmission 
to differentiate this potential mechanism from strict airborne 
transmission of individual viruses, which is generally consid-
ered an unlikely mechanism of Ebola transmission. Aerosol 
infection with Ebola delivered directly via inhalation has been 
demonstrated [8, 9], and multiple studies suggest aerosol 
transmission between infected and uninfected animals may 
occur [10–12]. Given the elevated risk of mucosal transmission 
of Ebola, particularly to healthcare workers [13–15], as well as 
the potential threat of aerosolized filovirus-based biowarfare 
agents, we sought to investigate the fate of Ebola deposited at 
mucosal surfaces.
Mucus membranes are characterized by a layer of mucus secre-
tions that can trap diverse foreign particles and pathogens [16, 17], 
facilitate their elimination through natural mucus clearance 
mechanisms [18, 19], and consequently reduce the flux of 
pathogens reaching target cells. Human airway mucus (AM) 
is likely responsible in part for the relatively modest transmis-
sion rates of many respiratory viruses [20–22], but it is also 
likely that AM can be reinforced to further limit the flux of 
pathogens reaching the underlying epithelium. We have pre-
viously shown that immunoglobulin G (IgG) Abs in cervi-
covaginal mucus can trap viruses via multiple low-affinity 
Fc-mucin bonds between IgG accumulated on the virus sur-
face and mucins, akin to a Velcro patch [23]. More recently, 
we also showed that the immobilization of H1N1 and H3N2 
influenza viruses in human AM is correlated with the presence 
of influenza-binding IgG and immunoglobulin A  (IgA) [24]. 
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Here, we investigate whether topically dosed IgG against Ebola 
may similarly trap Ebola in AM and facilitate its elimination 
from the airways.
METHODS
Preparation and Characterization of Ebola Pseudovirus
Ebola pseudoviruses were prepared by transfecting 293T cells 
with plasmids encoding Gag-mCherry and Ebola glycopro-
tein (GP) generously provided by Dr Suryaram Gummuluru 
(Department of Microbiology, Boston University School 
of Medicine) and Dr Ronald N.  Harty (Department of 
Pathobiology, School of Veterinary Medicine, University of 
Pennsylvania), respectively. We also prepared Ebola virus-like 
particles incorporating VP40 filovirus matrix protein, but the 
titers were insufficient for our microscopy and in vivo exper-
iments. Incorporation of Ebola GP into the pseudovirus was 
confirmed by Western blot. Additional details are provided in 
the Supplementary Materials.
Preparation and Characterization of Nanoparticles
Fluorescent, carboxyl-modified polystyrene beads (PS-COOH) 
and PEGylated nanoparticles (PS-PEG) sized approximately 
100  nm were prepared and characterized [25]. Additional 
details are provided in the Supplementary Materials.
Collection of Airway Mucus
Fresh human AM was obtained from healthy adult patients 
intubated for general anesthesia during elective surgery, fol-
lowing a protocol deemed nonhuman subjects research by 
the University of North Carolina at Chapel Hill Institutional 
Review Board. Additional details, including characterization of 
total immunoglobulin and IgG isotype levels, are provided in 
the Supplementary Materials.
Multiple Particle Tracking Analysis
Dilute particle solutions (~108–109 particles/mL, 1 µL) and differ-
ent Abs (2 µL, to a final concentration of 22 µg/mL) were added 
to 20 µL of fresh, undiluted AM in custom-made chambers, and 
samples were incubated for 1 hour at 37°C before microscopy. 
All conditions were tested in aliquots of the same AM samples, 
allowing direct comparison between conditions. Videos of the 
fluorescent particles in AM were recorded with MetaMorph 
software (Molecular Devices, Sunnyvale, CA) at a temporal 
resolution of 66.7  ms. Particle trajectories were analyzed using 
Video SpotTracker (University of North Carolina at Chapel Hill). 
Trajectories of n ≥ 130 particles per frame were analyzed for each 
experiment, and 8–9 independent experiments were performed. 
The coordinates of particle centroids were transformed into 
time-averaged mean-squared displacements (MSDs), calculated 
as <Δr2(τ)> = [x(t + τ) – x(t)]2 + [y(t + τ) – y(t)]2, where τ = time 
scale or time lag, from which distributions of MSDs and effective 
diffusivity (Deff) were calculated [25, 26]. Additional details are 
provided in the Supplementary Materials.
Ebola Pseudovirus Distribution in the Lung Airways
ZMapp cocktail (25  µL per mouse) or phosphate-buffered 
saline, followed by Ebola pseudovirus (25 µL per mouse) after a 
15-minute interval, was aerosolized and delivered using a Penn
Century Microsprayer to the airways of Balb/c mice (female,
8–10 weeks; n = 3 per condition). Mice were killed 30 minutes
after the final microsprayer instillation. Ebola pseudovirus dis-
tribution was quantified in transverse cryosections of the upper
airways. All experimental protocols were approved by the
University of North Carolina at Chapel Hill Institutional Animal 
Care and Use Committee and conform to the Declaration of
Helsinki conventions for the use and care of animals. Additional 
details are provided in the Supplementary Materials.
Statistical Analysis
Data averages are presented as means with standard error of the 
mean (SEM) indicated. Statistical comparisons were limited to 
2 groups. A 1-tailed, paired Student’s t test was used for all com-
parisons because different conditions were tested in aliquots of 
the same mucus samples. Differences were deemed significant 
at an alpha level of .05.
RESULTS
Rapid Penetration of Human Airway Mucus by Ebola Pseudovirus
Wild-type Ebola virus requires Biosafety Level 4 containment, 
which few laboratories have access to. Therefore, to investigate 
the fate of Ebola in mucus, we prepared fluorescent, noninfec-
tious Ebola pseudovirus comprised of human immunodeficiency 
virus type 1 (HIV-1) Gag-mCherry capsid proteins in the core 
and the Zaire GP, from the same species as in the West Africa epi-
demic in 2014–2016 [27, 28], on the surface. The same strategy 
was previously used to prepare HIV and influenza virus-like par-
ticles (VLP) [24, 29, 30]. Glycoprotein incorporation into Ebola 
pseudovirus was confirmed by Western blot (Supplementary 
Figure 1A), and dynamic light scattering showed that the pseudo-
virus possessed a hydrodynamic diameter of 102 ± 3 nm. All 3 
IgGs of the ZMapp cocktail bound specifically to the pseudovirus, 
confirming the presence of structurally intact GP (Supplementary 
Figure 1B).
To avoid dilution effects caused by the use of hypertonic 
saline to induce sputum expectoration, we obtained undiluted 
human AM directly from freshly extubated endotracheal tubes 
[24]. Ebola pseudoviruses were readily diffusive in all AM secre-
tions tested (Figure  1A; Supplementary Movie 1), exhibiting 
diffusive motion comparable with that of similarly sized, poly-
ethylene glycol–coated polystyrene (PS-PEG) (Supplementary 
Movie 2) nanoparticles engineered to evade adhesion to mucins 
and penetrate various mucus secretions [25, 31, 32]. In the same 
AM secretions, similarly sized carboxyl-modified polystyrene 
(PS-COOH) nanoparticles that are muco-adhesive were exten-
sively immobilized (Supplementary Movie 3), confirming that 
the rapid diffusivity observed for Ebola pseudovirus was not 
due to a degraded mucin matrix. Nearly all Ebola pseudoviruses 
(>50% in all samples; on average ~76%) possessed diffusivities 
in excess of approximately 200 nm, or twice the particle diame-
ter, at a time scale of 0.2667 seconds (Figure 1B). The geometri-
cally averaged ensemble mean squared displacement (<MSD>) 
of Ebola was only approximately 10-fold reduced compared 
with their theoretical speeds in buffer (Figure  1C; at a time 
scale of 0.2667 s), with a slope α of 0.80 for the log <MSD> ver-
sus log time scale plot (α = 1 for pure unobstructed Brownian 
diffusion—eg, particles in water—and α becomes smaller and 
approaches 0 as obstruction to Brownian diffusion increases). 
The geometrically averaged effective diffusivity (<Deff>) for 
Ebola pseudovirus was 0.43  µm2/s, approximately 150-fold 
higher than that of PS-COOH nanoparticles (Figure 1D).
Along the major conducting airways, the approximate 
thickness of mucus lining the bronchial airways is 50  µm, 
and the entire mucus blanket can be renewed in as little as 
15–30 minutes [19]. Therefore, we performed a first passage 
time estimate, using the measured diffusivities of individual 
pseudoviruses in AM to determine the time needed for viruses 
to diffuse across a 50-µm-thick AM layer. We found that upon 
airway deposition, nearly 10% of Ebola virions can penetrate 
the luminal AM layer within approximately 5 minutes, and 
nearly 50% can penetrate the AM layer in as little as 30 min-
utes. These results suggest limiting rapid Ebola penetration of 
AM may be an important strategy to reduce Ebola infection by 










































































































Figure 1. Diffusion in human airway mucus (AM) of Ebola pseudovirus and comparably sized polystyrene nanoparticles that are either carboxylated and mucoadhesive 
(PS-COOH) or modified with polyethylene glycol and muco-inert (PS-PEG). A, Representative trajectories for pseudovirus and particles exhibiting effective diffusivities within 
1 standard error of the mean of the ensemble average at a time scale of 0.2667 seconds. B, Distributions of the logarithms of individual particle effective diffusivities (Deff) 
at a time scale of 0.2667 seconds. Log Deff values to the left of the dashed line correspond to particles with displacements of less than approximately 200 nm (ie, roughly 
twice the particle diameter) within 0.2667 seconds or Deff approximately 20-fold reduced from theoretical diffusivity in water. C, Ensemble-averaged geometric mean square 
displacements (<MSD>) as a function of time scale. D, Ensemble geometric Deff at a timescale of 0.2667 seconds, and fraction of mobile particles are plotted for distinct 
samples with averages indicated by solid lines. Data represent the ensemble average of 8 independent AM specimens. Error bars represent standard error of the mean. 
* indicates a statistically significant difference compared with PS-COOH (P < .05) based on a 1-tailed, paired Student’s t test. Abbreviations: Deff, effective diffusivity; MSD, 
ensemble mean squared displacement; PS-COOH, carboxyl-modified polystyrene; PS-PEG, polyethylene glycol–coated polystyrene.
Immobilization of Ebola Pseudovirus in Human Airway Mucus 
Treated with ZMapp
Although total immunoglobulin and IgG isotype levels var-
ied substantially across AM samples (Supplementary Table 3), 
the rapid diffusion of Ebola pseudovirus in AM was remark-
ably consistent, suggesting endogenous Ab did not impact 
Ebola pseudovirus mobility. We next evaluated whether Ebola-
binding IgG, in the form of the 3 chimeric monoclonal anti-
body (mAb) cocktail ZMapp, could enhance the diffusional 
barrier properties of AM against Ebola. In agreement with 
our prior studies in cervicovaginal mucus [23, 33], addition of 
modest levels of Ebola-binding IgG into AM (on average ~2% 
of total IgG in AM) effectively reduced the mobility of Ebola 
pseudovirus, with the majority of pseudoviruses moving much 
less than their diameters over at least 20 seconds (Figure 2A; 
Supplementary Movie 4). Indeed, the <Deff> of Ebola pseudovi-
rus in ZMapp-treated AM decreased by approximately 27-fold 
compared with <Deff> in the same native AM secretions without 
Ab (Figure 3A). Likewise, the fraction of mobile pseudoviruses 
was reduced from 76% to 13% (Figure 2B), whereas <MSD> was 
>260-fold lower than theoretical pseudovirus speeds in buffer
(Figure 2C; at a time scale of 0.2667 s). The increased hindrance 
to rapid diffusion is also evident from the log <MSD> versus log 




































































































Figure 2. Diffusion of Ebola pseudovirus in human airway mucus (AM) that is untreated (no antibodies) or treated with either ZMapp or individual Ebola-binding immuno-
globulin G (IgG; c2G4, c13C6FR1, c4G7). A, Representative trajectories for pseudovirus exhibiting effective diffusivities within 1 standard error of the mean of the ensemble 
average at a time scale of 0.2667 seconds. B, Ensemble-averaged geometric mean square displacements (<MSD>) as a function of time scale. C, Distributions of the loga-
rithms of individual particle effective diffusivities (Deff) at a time scale of 0.2667 seconds. Log Deff values to the left of the dashed line correspond to particles with displace-
ments of less than approximately 200 nm (ie, roughly twice the particle diameter) within 0.2667 seconds or Deff approximately 20-fold reduced from theoretical diffusivity 
in water. Data represent the ensemble average of 8–9 independent AM specimens. Error bars represent standard error of the mean. * indicates a statistically significant 
difference compared with no antibodies (P < .05) based on a 1-tailed, paired Student’s t test. Abbreviations: Ab, antibody; Deff, effective diffusivity.
native (ie, Ab-free) and ZMapp-treated AM appeared identical 
in both size and brightness, suggesting ZMapp did not induce 
agglutination (ie, agglomeration of multiple Ebola pseudo-
viruses). Thus, the decrease in measured Ebola pseudovirus 
mobility is most likely attributed to immobilization of individ-
ual pseudoviruses due to polyvalent interactions between the 
array of pseudovirus-bound Abs and mucins. In contrast with 
ZMapp, control, nonspecific Abs did not alter Ebola pseudovi-
rus mobility.
To determine whether any particular mAb (c2G4, c13C6FR1, 
c4G7) within the ZMapp cocktail may confer superior 
“muco-trapping” potency, we measured the mobility of Ebola 
pseudovirus in different aliquots of the same AM specimens 
treated with the individual mAb. Interestingly, all 3 mAbs, 
including 1 with poor neutralizing activity against Ebola, were 
similarly effective in reducing the mobility of Ebola pseudovi-
rus in AM (Figure  2A; Supplementary Movies 5–7). Relative 
to the control with no Ab and similar to ZMapp, the <Deff> of 
Ebola pseudovirus was reduced by approximately 28-, 22-, and 
25-fold in AM treated with c2G4, c13C6FR1, and c4G7, respec-
tively. Similarly, the fraction of mobile Ebola pseudoviruses was 
reduced to 12%, 17%, and 15%, respectively.
To better illustrate how changes in mobility might alter 
the flux of virions reaching target cells, we again performed 
first-passage time analysis. The predicted time for 10% of Ebola 
pseudoviruses to diffuse across a 50-μm-thick mucus layer 
increased from approximately 5 minutes for native AM to 2.2, 
2.1, 1.6, and 1.7 hours for ZMapp-, c2G4-, c13C6FR1-, and 
c4G7-treated AM, respectively (Figure 3B). Similarly, the esti-
mated time for 50% of pseudoviruses to cross the mucus layer 
increased from 0.5 hours for native AM to 23, 22, 20, and 22 
hours, respectively. Because mucociliary clearance occurs on 
the order of 15–30 minutes [19], these results suggest that the 
vast majority of Ebola virions would be quickly trapped and 
eliminated from ZMapp-treated airways before they could pen-
etrate AM.
Rapid Elimination of Ebola Pseudovirus from the Lung Airways Treated 
with ZMapp
Lastly, we sought to evaluate whether ZMapp-induced trapping 
of viruses in mucus secretions ex vivo would translate to an 
improved AM barrier against Ebola and consequently altered 
distribution in the lung airways in vivo. Using a PennCentury 
microsprayer, we administered ZMapp or phosphate-buffered 
saline to the mouse lung, followed by addition of fluorescent 
Ebola pseudovirus 15 minutes later. In control mice, we observed 
substantial red fluorescence associated with Ebola pseudovirus 
throughout the lung airways, including fluorescence indicative 
of mucosal penetration and accumulation in the underlying 
airway epithelium (Figure  4A and 4B). In contrast, far fewer 
Figure 3. Diffusion and first-passage time of Ebola pseudovirus in human airway mucus (AM) that is untreated (no antibodies) or treated with either ZMapp or individual 
Ebola-binding immunoglobulin G (IgG; c2G4, c13C6FR1, c4G7). A, Ensemble geometric average effective diffusivities (Deff) at a timescale of 0.2667 seconds and fraction of 
mobile particles. B, Estimated time for 10% and 50% of pseudoviruses and particles to diffuse through a 50-µm-thick mucus layer. Data represent the ensemble average of 
8–9 independent AM specimens. Error bars represent standard error of the mean. * indicates a statistically significant difference compared with no antibodies (P < .05) based 
on a 1-tailed, paired Student’s t test. Abbreviations: Ab, antibody ; Deff, effective diffusivity.
Ebola pseudoviruses were present in the airways of mice treated 
with ZMapp (Figure 4C and 4D), presumably because pseudo-
viruses were trapped in the luminal mucus and rapidly cleared. 
Fluorescence levels in lung tissues of ZMapp-treated mice were 
almost 7-fold lower than those in control mice and only 3.5-fold 
above background. These results are consistent with previous 
observations that nanoparticles that bind to mucin mesh fibers 
are unable to penetrate the mucus layer and reach the underly-
ing epithelium.
DISCUSSION
We showed here that Ebola pseudoviruses readily penetrate 
fresh human AM secretions but can be effectively immobilized 
in AM by antigen-specific IgG (ZMapp). Trapping in turn facil-
itated rapid elimination of Ebola pseudovirus from the mouse 
airways. Although Ebola is generally not considered an airborne 
pathogen, aerosol transmission of Ebola virus is biologically 
plausible. Ebola virus is present in saliva, feces, blood, and other 
body fluids that can be aerosolized through Ebola symptoms (eg, 
Ebola pseudovirus in control
mouse trachea
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Figure 4. Ebola pseudovirus distribution in the mouse lung airways. A–D, Representative transverse 50-µm-thick frozen tissue sections showing the distribution of Ebola 
pseudovirus in the mouse trachea treated with phosphate-buffered saline (PBS) (A, B) or ZMapp (C, D). Red corresponds to Ebola pseudovirus, and blue corresponds to 
4',6-diamidino-2-phenylindole (DAPI)-stained cell nuclei. Arrows indicate the inner lining of the trachea. E, Quantification of Ebola pseudovirus signal in mouse trachea treated 
with PBS (control) or ZMapp compared with blank tissue. Data represent n = 3 mice per group with, on average, 10 tissue sections quantified per mouse. Error bars represent 
standard error of the mean. * indicates a statistically significant difference (P < .05) based on a 2-tailed Student’s t test assuming unequal variance.
coughing, vomiting, diarrhea) and through healthcare delivery 
(intubation, suctioning, delivery of nebulized medications) [5, 6]. 
Large droplets from a human sneeze can travel up to 1–2 m, 
whereas smaller droplets can travel up to 6–8 m away within 
seconds to a few minutes [34]. Studies have also found Ebola 
to survive in aerosol form for tens of minutes if not hours [35]. 
Ebola can initiate infection in cells present in the respiratory 
tract, and fatal respiratory infection has been observed in guinea 
pigs and nonhuman primates following intranasal and aerosol 
exposure [8, 9, 12]. Furthermore, Ebola transmission has been 
shown between infected and healthy macaques and between 
infected pigs and macaques without direct physical contact, 
likely through aerosol or droplet transmission [10, 11], although 
potential cross-contamination during animal husbandry prac-
tices could not be discounted entirely. A study frequently cited 
in arguments against airborne transmission found no detectable 
Ebola transmission when monkeys inoculated intramuscularly 
were housed in neighboring open-barred cages separated by a 
Plexiglas divider that prevented direct contact [36]; neverthe-
less, high viral titers were only detected in the blood, suggest-
ing virus titers in the lungs may not have achieved the critical 
titers necessary for respiratory transmission before the animals 
succumbed to systemic effects of infection. In contrast, recent 
studies in humans have reported substantial quantities of Ebola 
in respiratory secretions [37, 38], and pathology studies have 
also found viral antigen in lung tissue [1, 39]. Finally, aerosol 
dissemination of weaponized forms of filoviruses, a version 
of which has reportedly already been developed for Marburg 
virus [40], presents a substantial threat to both the military and 
potentially the general public. Altogether, these reports sub-
stantiate continued concern over aerosol transmission of Ebola 
virus and the need to explore strategies to prevent and treat 
Ebola transmission at mucosal membranes.
Although the secretion of mucus can increase in response 
to infection, mucus is generally viewed as a passive rather than 
adaptive barrier against pathogens and is consequently over-
looked in most studies of mucosal infection. The notion that 
Abs can work in tandem with mucus to reinforce the diffu-
sional barrier properties of mucus has remained largely unex-
plored, despite the fact that large quantities of Abs, including 
both IgG and IgA, are secreted into AM [41, 42]. Here, in good 
agreement with our recent discovery that IgG can trap herpes 
simplex virus type 1 in human cervicovaginal mucus [23], we 
showed that Ebola-binding mAbs, in the form of ZMapp, were 
able to facilitate effective trapping of the majority of Ebola 
pseudoviruses in AM. Antibody-mediated trapping of Ebola 
pseudovirus markedly reduced the fraction of virions pre-
dicted to penetrate the mucus layer over the first few minutes 
of exposure. Because trapped viruses are quickly eliminated by 
natural mucociliary clearance in the airways, ZMapp-mediated 
trapping of Ebola would likely reduce the total flux of viruses 
arriving at the airway epithelium and thus the likelihood and/
or severity of infection, rather than simply delaying the onset 
of infection. Consistent with this hypothesis, we observed top-
ical delivery of ZMapp into the mouse lung greatly reduced the 
amount of fluorescent Ebola pseudovirus retained in the con-
ducting airways within 30 minutes. Coupled with our earlier 
studies with genital mucus secretions [23, 33] and unpublished 
observations with gastrointestinal mucus, IgG-mediated trap-
ping of viruses in mucus appears to be a universal protective 
immune function across different mucosal surfaces that enables 
protection directly at the portals of entry for viral transmission. 
Importantly, adhesive interactions between the array of patho-
gen-bound Abs and mucus gel would explain how the other-
wise relatively nonadaptive and nonspecific biochemistry and 
microstructure of mucus secretions—the first line of defense 
against most infections—can be fortified with adaptive Abs to 
fend off a diverse and ever-changing spectrum of pathogens.
The concept of mucosal Ab prophylaxis and/or therapy based 
on Abs designed to work together with mucus to trap pathogens 
represents a unique and complementary approach in the arsenal 
of protective methods against infectious disease. First, the concept 
radically shifts the first line of defense against respiratory viruses 
to extracellular mucus gels instead of cellular targets, which is 
especially important against viruses that are either exception-
ally virulent (eg, Ebola) and/or without a cure (eg, HIV, Ebola). 
Second, Abs that trap viruses in mucus need not bind to neutral-
izing epitopes; this greatly broadens the potential antigen targets 
that can be exploited to achieve protection. Indeed, one of the 
mAbs in the ZMapp cocktail is actually a poor neutralizer. Third, 
because the viral load during the transmission episode at mucus 
membranes is likely low, the overall dose of mAbs needed at 
mucosal surfaces, either before or immediately following a high-
risk exposure event, may be substantially less than the mAb dose 
needed to treat a proliferating systemic infection. Thus, ZMapp 
delivered topically may be a particularly useful preventative mea-
sure or emergency intervention for populations at the highest 
risks of acquiring Ebola infections, such as healthcare workers, 
for reducing both the odds of becoming sick as well as the viral 
load entering the circulation following an exposure event.
Because of the continuous secretion and elimination of 
mucus coating the airways, the half-life of topically dosed Abs in 
the airways is relatively limited, likely necessitating at least once 
a day delivery to ensure adequate concentrations of mucosal 
Abs. Given the prolonged circulation times of IgG systemically, 
an attractive strategy could theoretically involve long-circu-
lating IgG that can also effectively extravasate and enter the 
AM. However, the extent to which systemically dosed IgG can 
enter the AM remains poorly understood. In guinea pig stud-
ies, intramuscular administration of a potent neutralizing IgG 
did not protect against influenza transmission, whereas intra-
nasal administration of the IgG did [43]. In humans, although 
the distribution of Ab isotypes appears to be similar in genital 
secretions compared with systemic Abs [23], total IgG and IgA 
in cervical mucus secretions correlate poorly with systemic lev-
els in normally cycling women [44, 45], reflecting substantial 
variations in Ab transudation across individuals. Thus, systemic 
delivery of IgG intended for mucosal protection may be chal-
lenging. In comparison, improvements in pulmonary delivery 
methods, including nebulizers, may enable uniform delivery of 
mAbs to the lung, while minimizing protein degradation and 
aggregation [46–48]. Combined with rapidly falling costs of Ab 
production, nebulizers may enable inhaled mAbs for prophy-
laxis to become a practical reality.
One limitation to our work is that we did not have sufficient 
AM sample volume to test control virus or control Abs in the 
same samples. Nevertheless, we validated in pilot studies that 
control Abs do not alter the mobility of Ebola pseudovirus com-
pared with no treatment control. We have also shown that wild-
type influenza viruses and influenza VLP, but not HIV VLP, 
are trapped in the same AM containing influenza-specific Abs 
[24]. Finally, we have previously demonstrated using multiple 
viruses/particles in different mucus types that control, nonspe-
cific Abs do not trap the viruses/particles, whereas specific Abs 
do so potently [23, 33]. We were also not able to test wild-type 
Ebola virus in either particle tracking or in vivo experiments. 
Although our pseudovirus has the same surface GPs as wild-
type virus, it is possible that differences in morphology or GP 
density can lead to varying trapping efficiency by Ebola-binding 
IgG. Because of Biosafety Level 4 requirements, we were unable 
to directly demonstrate protective efficacy against Ebola in 
vivo, although we have shown that trapping in mucus and rapid 
clearance of viral particles from the mouse vagina correlate to 
protection against herpes [23]. Lastly, because of major differ-
ences in lung physiology, rodent studies are ill suited to inform 
the local pharmacokinetics of inhaled Abs in the human lung. 
Although prior work suggests the half-life of inhaled Abs in 
humans is approximately 1 day [49, 50], studies exploring the 
effectiveness and potential duration of this strategy in larger 
animal models will be needed for translation into humans.
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